1. P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study. (25th January 2019) Authors: Bressler, B; Mantzaris, G; Silverberg, M; Zezos, P; Stein, D; Colby, C; Lissoos, T; Lopez, C; Natsios, A; Radulescu, G; Patel, H; Demuth, D; Yarur, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study. (15th January 2020) Authors: Bressler, B; Yarur, A; Kopylov, U; Bassel, M; Brett, N; Colby, C; Lopez, C; Saha, S; Kifnidi, C; Agboton, C; Adsul, S; Demuth, D; Luo, M; Wang, S; Mantzaris, G J Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 797 IMPROVING GERIATRIC CARE IN THE EMERGENCY DEPARTMENT; TREATT PROJECT: THE RAPID EARLY ASSESSMENT THERAPY TEAM. (8th March 2022) Authors: Foxley, H; Colby, C; Swin, J; Leyland, R Journal: Age and ageing Issue: Volume 51(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗